Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enbrel Five-Year Data Could Bolster Case For Long-Term RA Efficacy

Executive Summary

Immunex' Enbrel five-year data could support the company's case that the product delays radiographic progression in long-standing rheumatoid arthritis.

You may also be interested in...



Enbrel Promotions May Use AUC Data, Erosion Scores, Not Superiority Claims

Immunex' Enbrel promotions may use data on percentages of patients with no increase in erosion scores and area under the curve data, but may not use the data to make superiority claims to methotrexate, the approval letter for a new indication for Enbrel states.

Enbrel Promotions May Use AUC Data, Erosion Scores, Not Superiority Claims

Immunex' Enbrel promotions may use data on percentages of patients with no increase in erosion scores and area under the curve data, but may not use the data to make superiority claims to methotrexate, the approval letter for a new indication for Enbrel states.

Immunex Plans Enbrel Early RA Consumer Ad Campaign For Summer Launch

Immunex will roll out a new series of direct-to-consumer print ads to support Enbrel for early rheumatoid arthritis following FDA approval of the new indication, expected this summer.

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel